Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab

OBJECTIVE: Patients with HER2-positive metastatic breast cancer (MBC) benefit from trastuzumab-based therapy but eventually develop intrinsic or acquired resistance. Whether plasma HER2 gene copy number (GCN) could predict survival after trastuzumab treatment remained controversial. We evaluated the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Ran, Ran, Huang, Wenfa, Liu, Yaxin, Shao, Lin, Liu, Xiaoran, Niu, Yunyun, Kong, Weiyao, Bo, Shiping, Rugo, Hope S, Lu, Sijia, Li, Huiping
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7245474/
https://ncbi.nlm.nih.gov/pubmed/32547071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S240990
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky